Group 7 Bioresonance protocol applied to metastatic cancer Rife Digital Professional V3 (RDPV3 GROUP 7)
This group represents specific signal intensities used within the metastatic treatment framework, The group will correspond to the mentioned particular metastatic pattern: a primary tumor originating in the lungs, with secondary spread to the esophagus and subsequently to the brain. The grouping suggests that this configuration of disease progression does confirm a Group 7 treatment protocol.
From a clinical description standpoint, the disease progression reflects a typical metastatic pathway in advanced cancer, where malignant cells disseminate from the primary pulmonary site through lymphatic or hematogenous routes. The involvement of the esophagus indicates regional extension or secondary implantation, while brain metastasis signifies systemic spread and advanced-stage disease. The Rife Digital Frequency treatment is designed to correspond to specific pathological states, with the intention of influencing biological processes through frequency-based intervention.
Cancer: Metastasis [Organ] RDPV3 GROUP 7:
0.13, 0.46, 0.83, 12.69, 93.5, 221.5, 434.71, 512.33, 667, 753.07
Given the extensive area requiring treatment, it is advisable to consider the use of the Beamer Tech full-body mat. This device can be positioned on a bed, allowing for comprehensive coverage and facilitating treatment across the entire body. You can also use the Rife Healing Mat, same thing, just smaller.
